Detailed information for compound 156422

Basic information

Technical information
  • TDR Targets ID: 156422
  • Name: N-[2-(5-methoxy-1-benzofuran-3-yl)ethyl]aceta mide
  • MW: 233.263 | Formula: C13H15NO3
  • H donors: 1 H acceptors: 1 LogP: 1.87 Rotable bonds: 5
    Rule of 5 violations (Lipinski): 1
  • SMILES: COc1ccc2c(c1)c(CCNC(=O)C)co2
  • InChi: 1S/C13H15NO3/c1-9(15)14-6-5-10-8-17-13-4-3-11(16-2)7-12(10)13/h3-4,7-8H,5-6H2,1-2H3,(H,14,15)
  • InChiKey: BTVRPXLAXZPZPV-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

  • N-[2-(5-methoxybenzofuran-3-yl)ethyl]acetamide
  • N-[2-(5-methoxy-3-benzofuranyl)ethyl]acetamide
  • N-[2-(5-methoxy-1-benzofuran-3-yl)ethyl]ethanamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens melatonin receptor 1A Starlite/ChEMBL References
Homo sapiens melatonin receptor 1B Starlite/ChEMBL References
Homo sapiens NAD(P)H dehydrogenase, quinone 2 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Giardia lamblia NADPH oxidoreductase, putative Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Giardia lamblia NADPH oxidoreductase, putative Get druggable targets OG5_130380 All targets in OG5_130380
Giardia lamblia NADPH oxidoreductase, putative Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis conserved hypothetical protein Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis NAD(P)H dehydrogenase, putative Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis NAD(P)H dehydrogenase, putative Get druggable targets OG5_130380 All targets in OG5_130380
Trichomonas vaginalis NAD(P)H dehydrogenase, putative Get druggable targets OG5_130380 All targets in OG5_130380

By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Brugia malayi hypothetical protein melatonin receptor 1B 362 aa 329 aa 18.8 %
Trichomonas vaginalis NAD(P)H dehydrogenase, putative NAD(P)H dehydrogenase, quinone 2 231 aa 213 aa 26.3 %

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Giardia lamblia NADPH oxidoreductase, putative 0.0096 1 0.5
Trichomonas vaginalis conserved hypothetical protein 0.0096 1 1
Trichomonas vaginalis conserved hypothetical protein 0.0096 1 1
Trichomonas vaginalis conserved hypothetical protein 0.0096 1 1
Trichomonas vaginalis conserved hypothetical protein 0.0096 1 1
Trichomonas vaginalis conserved hypothetical protein 0.0096 1 1
Trichomonas vaginalis conserved hypothetical protein 0.0096 1 1
Trichomonas vaginalis conserved hypothetical protein 0.0096 1 1
Trichomonas vaginalis NAD(P)H dehydrogenase, putative 0.0096 1 1
Trichomonas vaginalis NAD(P)H dehydrogenase, putative 0.0096 1 1
Giardia lamblia NADPH oxidoreductase, putative 0.0096 1 0.5
Trichomonas vaginalis conserved hypothetical protein 0.0096 1 1
Trichomonas vaginalis NAD(P)H dehydrogenase, putative 0.0096 1 1
Trichomonas vaginalis conserved hypothetical protein 0.0096 1 1
Trichomonas vaginalis conserved hypothetical protein 0.0096 1 1
Trichomonas vaginalis conserved hypothetical protein 0.0096 1 1
Trichomonas vaginalis conserved hypothetical protein 0.0096 1 1
Trichomonas vaginalis conserved hypothetical protein 0.0096 1 1

Activities

Activity type Activity value Assay description Source Reference
Activity (functional) Blocking the inhibitory effect of 1 nM melatonin. ChEMBL. 7932550
Activity (functional) 0 Blocking the inhibitory effect of 1 nM melatonin. ChEMBL. 7932550
cAMP activity index (functional) = 1.45 Activity (expressed as cAMP index) measured by the melatonin-mediated inhibition of forskolin-stimulated cAMP production ChEMBL. 7932550
cAMP activity index (functional) = 1.45 Activity (expressed as cAMP index) measured by the melatonin-mediated inhibition of forskolin-stimulated cAMP production ChEMBL. 7932550
IC50 (binding) = 7.19 Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells ChEMBL. 18400335
IC50 (binding) = 8.8 Melatonin receptor type 1A binding affinity measured using 2-[125I]-iodomelatonin on ovine pars tuberalis membrane homogenates. ChEMBL. 9804685
IC50 (binding) = 0.0000000017 M Monophasic inhibitory concentration against melatonin receptor was measured on ovine pars tuberalis membrane. ChEMBL. 7932550
IC50 (binding) = 0.0000000017 M Monophasic inhibitory concentration against melatonin receptor was measured on ovine pars tuberalis membrane. ChEMBL. 7932550
IC50 (binding) = 0.6 nM Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in HEK293 cells ChEMBL. 18372181
IC50 (binding) = 0.7 nM Displacement of 2-[125I]iodomelatonin from human MT2 receptor expressed in HEK293 cells ChEMBL. 18372181
Kd (binding) = 0.000000000859 Binding affinity to melatonin receptor measured on ovine pars tuberalis membrane ChEMBL. 7932550
Kd (binding) = 0.000000000859 Binding affinity to melatonin receptor measured on ovine pars tuberalis membrane ChEMBL. 7932550
Ki (binding) = 0.15 nM Binding affinity on human melatonin receptor type 1A stably transfected in human embryonic kidney (HEK 293) using 2-[125I]-iodomelatonin as radioligand. ChEMBL. 12061881
Ki (binding) = 0.15 nM Binding affinity on human melatonin receptor type 1A stably transfected in human embryonic kidney (HEK 293) using 2-[125I]-iodomelatonin as radioligand. ChEMBL. 12061881
Ki (binding) = 0.15 nM Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in CHO cell membranes after 120 mins ChEMBL. 26820449
Ki (binding) = 0.15 nM Displacement of [125I]2-Iodomelatonin from human MT1 receptor expressed in HEK293 cells after 120 mins by radioligand competition assay ChEMBL. 26785296
Ki (binding) = 0.34 nM Binding affinity on human melatonin receptor type 1B stably transfected in human embryonic kidney (HEK 293) cells using 2-[125I]-iodomelatonin as radioligand. ChEMBL. 12061881
Ki (binding) = 0.34 nM Binding affinity on human melatonin receptor type 1B stably transfected in human embryonic kidney (HEK 293) cells using 2-[125I]-iodomelatonin as radioligand. ChEMBL. 12061881
Ki (binding) = 0.34 nM Displacement of 2-[125I]iodomelatonin from human MT2 receptor expressed in CHO cell membranes after 120 mins ChEMBL. 26820449
Ki (binding) = 0.34 nM Displacement of [125I]2-Iodomelatonin from human MT2 receptor expressed in HEK293 cells after 120 mins by radioligand competition assay ChEMBL. 26785296
Log IC50 (binding) = 8.8 Melatonin receptor type 1A binding affinity measured using 2-[125I]-iodomelatonin on ovine pars tuberalis membrane homogenates. ChEMBL. 9804685
pC1 (binding) = 3.469 Binding affinity against melatonin receptor type 1B ChEMBL. 15177448
pC1 (binding) = 3.824 Binding affinity against Melatonin receptor type 1A ChEMBL. 15177448
pC1 (binding) = 3.469 Binding affinity against melatonin receptor type 1B ChEMBL. 15177448
pC1 (binding) = 3.824 Binding affinity against Melatonin receptor type 1A ChEMBL. 15177448
pRA (binding) = -0.97 Negative logarithm of relative affinity (pRA) towards melatonin receptor (relative to N-actyl-5-methoxytryptamine (aMT)) ChEMBL. 9748358
pRA (binding) = -0.97 Negative logarithm of relative affinity (pRA) towards melatonin receptor (relative to N-actyl-5-methoxytryptamine (aMT)) ChEMBL. 9748358
Ratio (binding) = 0.5 Melatonin receptor type 1A/Melatonin receptor type 1B affinity ratio. ChEMBL. 12061881
Ratio (binding) = 0.5 Melatonin receptor type 1A/Melatonin receptor type 1B affinity ratio. ChEMBL. 12061881
Selectivity (binding) = -0.355 Selectivity of the compound (pC2-PC1) was determined ChEMBL. 15177448
Selectivity (binding) = -0.355 Selectivity of the compound (pC2-PC1) was determined ChEMBL. 15177448

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

9 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.